NCT06239194 - Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

115

Participants

Timeline

Start Date

June 12, 2024

Primary Completion Date

August 31, 2028

Study Completion Date

February 28, 2029

Conditions

Biliary Tract CancerBreast CancerCervical CancerColon CancerEndometrial CancerEsophageal CancerGastric CancerGastroEsophageal CancerHead and Neck CancerHepatocellular CancerNon-small Cell Lung CancerPancreatic CancerProstate CancerRectal CancerRenal CancerThyroid Cancer

Interventions

DRUG

MDX2001

MDX2001 intravenous infusion

Trial Locations (6)

33136

RECRUITING

Sylvester Comprehensive Cancer Center - University of Miami Health System, Miami

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

77030

RECRUITING

MD Anderson Cancer Center, Houston

78229

RECRUITING

NEXT Oncology, San Antonio

80218

RECRUITING

Sarah Cannon Research Institute, Denver

02114

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors

lead

ModeX Therapeutics, An OPKO Health Company

INDUSTRY